PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 11 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 3 years ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 3 years 2 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 3 years 2 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 3 years 2 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 3 years 3 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 3 years 3 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 3 years 4 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
PRESS RELEASE published on 04/17/2023 at 12:45, 3 years 4 months ago NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
PRESS RELEASE published on 04/04/2023 at 13:45, 3 years 5 months ago NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Published on 09/14/2026 at 15:15, 2 hours 34 minutes ago Mako Mining Announces a Non-Binding Letter of Intent to Enter a Gold Purchase Agreement with Sailfish Royalty to Lower its Cost of Capital and Facilitate Shareholder Returns and Accretive Acquisitions
Published on 09/14/2026 at 15:00, 2 hours 49 minutes ago Vox Royalty Completes Acquisitions of White Dam, Kalman and Sylvania Australian Gold & Copper Royalties
Published on 09/14/2026 at 14:30, 3 hours 19 minutes ago Goldcliff Finalizes Drill Plans for New East Breccia Gold-Silver Target at Kettle Valley
Published on 09/14/2026 at 14:00, 3 hours 49 minutes ago Revolve Completes Acquisition of 9.6 MW Operating Wind Project in the US
Published on 09/14/2026 at 14:00, 3 hours 49 minutes ago Kinross Encounters Gold and Copper in Recent Drill Holes with Gold Values up to 6 g/t, Kinross Drilling to Continue on Dixie Halo
Published on 09/14/2026 at 17:35, 13 minutes ago CATL Launches TECTRANS II at IAA Transportation 2026 to Accelerate Global Commercial Vehicle Electrification
Published on 09/14/2026 at 17:05, 43 minutes ago KHLOÉ KARDASHIAN ANNOUNCES RETAIL EXPANSION INTO SEPHORA WITH HER GLOBALLY ACCLAIMED FRAGRANCE PORTFOLIO WITH LUXE BRANDS
Published on 09/14/2026 at 17:00, 49 minutes ago EQS-Adhoc: Fourcore Tech Finance Ltd.: Update on capital structure realignment and timing of September 2026 interest payments
Published on 09/14/2026 at 16:52, 56 minutes ago BERENBERG initiates coverage and recommends buying 2G Energy share
Published on 09/14/2026 at 16:35, 1 hour 13 minutes ago Neolix Joins Espaces-Mobilités and Stalem to Pilot L4 Autonomous RoboVans in Brussels
Published on 09/14/2026 at 17:35, 14 minutes ago Disclosure of transactions in own shares from September 7 to September 11, 2026
Published on 09/14/2026 at 16:15, 1 hour 33 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of August 31, 2026
Published on 09/11/2026 at 07:00, 3 days 10 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
